DOCSLIB.ORG

Quick Reference Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quick Reference Formulary Somerset CCG Quick Reference Formulary – First and Second Line Formulary Options Green is the CCG formulary preferred brand Blue is suitable for self care and available to buy OTC May 2021 Chapter 1 Gastro-intestinal system NICE guideline on chronic heart failure 2.8.2 Anticoagulants • Umeclidinium – Incruse Adrenaline NICE Guideline for reflux and 2.2 Diuretic NICE guideline on DVT Ellipta® • Emerade® dyspepsia • Indapamide • Enoxaparin LAMA/LABA Combination Inhalers 3.7 Mucolytics 1.1 Dyspepsia and Reflux disease • Furosemide • Warfarin • Anoro Ellipta® or Duaklir • Carbocisteine Antacids • Spironolactone • DOACs – Dabigatran, Genuair® or Ultibro • Acetylcysteine as NACSYS® • Mucogel® • Eplerenone rivaroxaban, apixaban, Breezhale® or Spiolto Alginate 2.3 Aniti-arrhythmic edoxaban Respimat® Chapter 4 Central Nervous System • Peptac® • Amiodarone 2.9 Antiplatelets Theophylline – prescribe by brand 4.1 Hypnotic and Anxiolytics • Acidex Advance® 2.4 Betablocker • Aspirin as Danamep®, • Theophylline MR – NHS Sleep and Tiredness guide 1.2 Antispasmodic • Bisoprolol clopidogrel, dipyridamole Uniphyllin Continus®, CCG hypnotics and anxiolytics • Mebeverine tabs • Atenolol MR, prasugrel, ticagrelor Nuelin SA® Hypnotics 1.3.5 PPI • Metoprolol 2.12 Lipid Regulating Drugs • Zoplidem, zopiclone, CCG PPI deprescribing algorithm 2.5.5 ACE-inhibitors Statins 3.2 Corticosteroids (prescribe by diazepam • Lansoprazole, omeprazole, NICE guideline on hypertension • Atorvastatin, rosuvastatin, brand) NICE guideline on Anxiolytics pantoprazole, • Lisinopril Other lipid lowering corticosteroids in asthma • Diazepam esomeprazole • Ramipril caps • Ezetimibe • Beclometasone– MDI as 4.2 Antipsychotics 1.4 Acute diarrhoea ARBs Fibrates Sopradec® or Kelhale®, DPI • Risperidone, olanzapine, NICE guideline for diarrhoea in under • Losartan • Fenofibrate micronized as Easyhaler® aripiprazole, quetiapine 5s • Candesartan • Budesonide - Easyhaler® • Quetiapine XL – Sondate • Dioralyte®, Loperamide Centrally acting antihypertensive Chapter 3 Respiratory System Combination Inhalers ICS/LABA XL®, Zaluron XL® 1.5 Chronic Bowel Disorders • Methyldopa NICE guideline on COPD • Fluticasone/ salmeterol 4.2.3 Antimanic drugs NICE guideline for colitis • Moxonidine CCG respiratory home page MDI as Combisal® or • Lithium – must be Prescribe mesalazine by brand Alpha-blocker CCG Inhaler Venn Diagram AirFluSal®, DPI as prescribed by brand • Mesalazine 400mg as • Doxazosin - Doxadura® 3.1 Bronchodilators Fusacomb Easyhaler® or 4.3 Antidepressants Zintasa EC®, 500mg as 2.6 Nitrates SABA Stalpex® SSRIs and Tricyclic Pentasa SR®, sachets as • GTN spray • Salbutamol CFC MDI • Budesonide/ formoterol • Fluoxetine, sertraline, Salofalk® • Isosorbide mononitrate • DPI - Salbutamol DPI as Fobumix® citalopram 1.6 Laxatives • Isosorbide mononitrate SR Easyhaler® Triple Combination LABA/LAMA/ICS • Lofepramine, amitriptyline NICE guideline for constipation – Tardisc XL®, Monomil LABA • Vilanterol/fluticasone • Mirtazapine, venlafaxine Stimulants XL®, Chemydur XL® • Formoterol DPI – furoate/umeclidinium – • Venlafaxine MR – Vensir • Bisacodyl or senna or CCB - Dihydropyridines Easyhaler® DPI as Trelegy Ellipta® XL®, Venlalic XL®, Vencarm docusate, glycerol • Amlodipine • Formoterol MDI - Atimos® • Beclometasone/formoterol XL® suppositories • Lacidipine • Salmeterol – Soltel® or /glycopyrronium – MDI as 4.5.1 Obesity Osmotic • Lercanidipine Serevent Accuhaler® Trimbow® • Orlistat – P med can be • Macrogol - Laxido® or CCB – Rate limiting prescribe by brand • Indacaterol – Onbrez • Mometasone/indacaterol/ bought Cosmocol® • Diltiazem MR – Zemtard Breezhaler® glycopyrronium DPI as 4.7 Analgesics Bulk forming Paracetamol prescribing guidelines XL®, Slozem® • Olodaterol – Striverdi Enerzair Breezhaler® • Ispaghula husk – Fybogel • Paracetamol • Verapamil Respimat® Spacer Devices • Lactulose Weak Opioids • Verapamil MR – Half- LAMA • EasyChamber® or 1.7 Anal and rectal disorders Securon SR® or Securon AeroChamber Plus® • Codeine Haemorrhoids & Anal Fissures • Ipratropium MDI SR® 3.3.2 Leukotriene Receptor • Co-codamol 30/500 – • Anusol or Scheriproct® • Aclidinium bromide – Eklira 2.6.3 Potassium Channel Activator Antagonists Zapain® • GTN ointment -Rectogesic® Genuair® • Nicorandil • Montelukast • Tramadol – MR as Marol® • Glycopyrronium bromide - Sinus Node Regulator 3.4.1 Antihistimes bd or Tradorec XL® od Chapter 2 Cardiovascular System Seebri Breezhaler® • Ivabradine • Non sedating – loratadine, Strong Opioids NICE guideline on strokes • Tiotropium -Braltus Zonda® 2.6.4 Vasodilators cetirizine • Morphine – Zomorph®, NICE guideline on atrial fibrillation or Spiriva Respimat® • Naftidrofuryl • Sedating - chlorphenamine Morphgesic SR® Somerset CCG Quick Reference Formulary – First and Second Line Formulary Options Green is the CCG formulary preferred brand Blue is suitable for self care and available to buy OTC May 2021 • Fentanyl – Matrifen®, Chapter 6 Endocrine System Thiazolidinediones 5-ARIs • Ethinylestradiol / Fencino®, Mezolar® NHS diabetes guide • Pioglitazone • Finasteride levonorgestrel – Levest®, • Buprenorphine – Bunov®, CCG diabetes page 6.5.2 Posterior pituitary hormones Maexeni®, Rigevidon® Reletrans®, Butec® 6.1.1 Insulins and Disposables DPP-4 inhibitors and antagonists • Ethinylestradiol/ Insulin must be prescribed by brand • Alogliptin • Desmopressin - Noqdirna® norgestimate – Lizinna®, 4.7.3 Neuropathic Pain • Linagliptin, saxagliptin, Cilique® • Amitriptyline, duloxetine, Short acting sitagliptin, vildagliptin Chapter 6.6 – Drugs affecting Bone • Ethinylestradiol/gestodene gabapentin, pregabalin • Aspart – Novorapid Rapid acting insulin secretagogue Metabolism – Millinette® 30/75 4.7.4 Antimigraine • Lispro – Insulin Lispro • Repaglinide NICE advice on bisphosphonates • Ethinylestradiol/desogestr Acute Analgesia Sanofi® SGLT-2 inhibitor Patient guide to bisphosphonates el – Cimizt® 30/150, • Ibuprofen, paracetamol • Soluble – Human Actrapid, • Ertugliflozin, empagliflozin, Prevention of osteoporosis Munalea® 30/150, Anti-emetic Insuman Rapid, Humulin S dapagliflozin, canagliflozin • Alendronic acid, Gedarel® 30/150 • Domperidone - MHRA, Intermediate acting GLP-1 mimetic risedronate, ibandronate • Ethinylestradiol/drospireno metoclopramide - MHRA, • Biphasic isophane – • Lixisenatide Calcium with vitamin D – only if ne – Yacella® prochlorperazine Insuman Combe 15,25 & • Exenatide, liraglutide, bisphosphonate prescribed • Mestranol/norethisterone Triptans 50, Humulin M3 dulaglutide, semaglutide • Theical®, Accrete®, Adcal - Norinyl-1® • Sumatriptan, frovatriptan, • Biphasic insulin aspart – 6.2 Thyroid and Anti-thyroid drugs D3®, Evacal D3®, Calci-D® • Ethinylestradiol/ naratriptan, naratriptan NovoMix 30 Thyroid hormones Chapter 7 Obstetrics, Gynaecology norethisterone (tri phasic) - Prophylaxis • Biphasic Insulin lispro – • Levothyroxine and Urinary-tract Disorders Synphase® • Propranol, topiramate Humalog Mix 25 & 50 Anti-thyroid hormones 7.2 Treatment of Vaginal and Vulval • Ethinylestradiol / 4.10 Substance Dependence • Isophane insulin – Insuman • Carbimazole, Conditions levonorgestrel (tri phasic) – NHS Smokefree website Basal, Human Insulatard, propylthiouracil Atrophy TriRegol®, Logynon®, NICE guideline on stopping smoking in Humulin I 6.3 Corticosteroids • Estradiol – Ovestin®, Logynon® ED pregnancy Long acting • Prednisolone, Vagirux® 7.3.2Progesteron only contraceptives • NRT – patches, gum, • Insulin glargine – hydrocortisone Fungal infections (POP) lozenge, spray Semglee®, Abasaglar, 6.4.1 Hormone Replacement Therapy • Fluconazole, clotrimazole • Desogestrel • Bupropion, varenicline Lantus Prescribe by brand 7.3 Contraceptives • Norethisterone – Noriday® Opioid Dependence • Insulin detemir – Levemir Unopposed oestrogen Methods of contraception • Levonorgestrel – • Methadone – Physeptone® • Insulin degludec – Tresiba • Elleste Solo®, Bedol®, Contraceptive pill suitable for patients Norgeston® • Buprenorphine sublingual Pen Needles and Lancets Evorel® taking hepatic enzyme-inducing drugs 7.3.2.3 Intra uterine POP tabs Compatibility chart Cyclical combined guideline • Mirena®, Jaydess®, 4.11 Drugs for Dementia • Microdot Max®, GlucoRx • Elleste Duet®, Clinorette®, FSRH guide to Drug Interactions with Levosert® Initiated by specialist only Carepoint®, GlucoRx Cyclo-progynova®, Evorel Hormonal Contraception Long acting reversible contraception AChE Inhibitors Carepoint Ultra® Sequi® 7.3.1 Combined hormonal • Medroxy-progesterone – • Donepezil • Microdot Plus®, Fastclix®, Continuous combined contraceptives Depo-Provera®, Sayana • Galantamine – MR as GlucoRx® • Kliofem®, Kliovance®, Low strength Press® Gatalin XL® or Gazylan XL® 6.1.2 Drugs used in Diabetes Premique Low Dose®, • Ethinylestradiol/gestodene • Etonogestrel – Nexplanon® • Rivastigmine – patches as NICE guideline on adults with type 2 Evorel Conti® – Millinette 20/75® 7.3.5 Emergency Hormonal Alzest® diabetes Progestogens • Ethinylestradiol/ Contraception NMDA-receptor Antagonist DVLA guidance on driving with • Norethisterone, desogestrel – Bimizza • Levonorgestrel – • Memantine diabetes medroxyprogesterone 20/150®, Munalea Upostelle® Biguanides • Levonorgestrel - Mirena® 20/150®, Gedarel 20/150® • Ulipristal – EllaOne® • Metformin – MR as 6.4.2 Male Sex Hormones and • Ethinylestradiol / Uterine Fibroids Chapter 5 Infections Sukkarto SR®, Yaltormin Antagonists drospirenone - Eloine® • Ulipristal - Esmya® Refer to separate infection quick PR®, Glucorex® Testosterone Standard strength 7.4.1 Drugs
Load more

Recommended publications
  • Zhejiang Xianju Pharmaceutical Co. Ltd
    No.1, Xianyao Road, Xianju, Zhejiang, China, 317300 Xianju Pharma Outline Outline I. Brief Introduction II. Quality Unit III. Production System IV. EHS System I. Brief Introduction Xianju Pharma Zhejiang Xianju Pharmaceutical Co., Ltd. A professional manufacturer of steroids and hormone products with largest scale and maximum varieties in China. A state-designated manufacturer of contraceptive drugs in China. Company Milestones Jan 1972 Foundation of company May 1997 Incorporated into Zhejiang Medicine Co., Ltd Oct. 1999 Listed in Shanghai Stock Market Jun. 2000 Reorganized into Xianju Pharmaceutical Co., Ltd Dec. 2001 Reformed to Zhejiang Xianju Pharmaceutical Co., Ltd Jan. 2010 listed in Shenzhen Stock Market Location of Xianju There are six airports around Shanghai Xianju, which makes us easily accessible for our partners. Headquarter Hangzhou Located in Xianju, Taizhou City Ningbo Yangfu Site (FPPs) Located in Yangfu, Xianju, Taizhou Yiwu City 6.8km from headquarter Duqiao Site (APIs) Located in LinHai, TaiZhou City, 82.9km from headquarter Taizhou Wenzhou Yangfu Site (APIs) Under construction, finish at 2017 Company Organization General Manager Vice G.M for Vice G.M Vice G.M for Vice G.M for Vice G.M for Quality Director Sales for Market Administration Finance Technology Finance Dept Finance Dept Application Tech Dept Endineering Construction Domestic DrugRegistrationDept. Research& Development Dept. Marketing Dept. Marketing Quality Control Quality Domestic Trading Dept International TradeDep Quality Assurance For FPP Quality Assurance For API Regulatory AffairsDept Human Resource Dept Information Technology Dept Dept Enterprise Management Dept Affairs Administrative Taizhou Xianju Quality System Quality Xianju Taizhou . t G.M. Assistant EHS Dept Production Management Dept G.M.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • Superior Nuclear Receptor Selectivity and Therapeutic Index of Methylprednisolone Aceponate Versus Mometasone Furoate
    DOI:10.1111/j.1600-0625.2007.00597.x www.blackwellpublishing.com/EXD Original Article Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate Parham Mirshahpanah1, Wolf-Dietrich Do¨ cke2, Udo Merbold2, Khusru Asadullah2, Lars Ro¨se2, Heike Scha¨ cke2 and Thomas M. Zollner1 1Research Business Area Dermatology, Berlex Biosciences, Richmond, CA, USA; 2Corporate Research Area Inflammation, Bayer Schering Pharma, Berlin, Germany Correspondence: Thomas M. Zollner, TRG Inflammation, Bayer Schering Pharma, Berlin, Germany, Tel.: +1 510 669 4272, e-mail: [email protected] Accepted for publication 18 June 2007 Abstract: Although introduced more than 50 years ago, topical a relevant rodent model in vivo. We demonstrate that glucocorticoids are still the first line therapy for many methylprednisolone aceponate displays higher specificity in inflammatory skin disorders such as atopic eczema, contact nuclear receptor binding compared with mometasone furoate. dermatitis and many others. Recently, significant improvements Methylprednisolone aceponate was also markedly superior in have been made to optimize the ratio of desired to unwanted terms of minimizing induction of skin atrophy or telangiectasias effects. While with early compounds such as triamcinolone, when compared with mometasone furoate. Based on these topical side effects such as skin atrophy and telangiectasias can be observations, methylprednisolone aceponate is expected to have a observed rather frequently, newer drugs such as methyl- greater therapeutic index as compared with mometasone furoate, prednisolone aceponate or mometasone furoate have a at least in the test systems used here. The degree to which this significantly improved therapeutic index. The present study observation may translate into a clinical setting requires compared these two modern topical glucocorticoids, which confirmation.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • Mometasone Powder Rationale for Inclusion In
    MOMETASONE POWDER RATIONALE FOR INCLUSION IN PA PROGRAM Background Mometasone is a corticosteroid demonstrating potent anti-inflammatory activity able to decrease inflammation through a mechanism of action that is not known. However, corticosteroids are thought to act by the induction of phospholipase A2, which leads to the inhibition of a common precursor for potent inflammatory mediators. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption (1). Mometasone is commercially available in the following dosage forms: topical cream, topical lotion, topical ointment, nasal spray and as a powder for inhalation. Regulatory Status FDA approved topical indication: Mometasone is a corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age and older (1). The safety and efficacy of mometasone have not been established in pediatric patients below 2 years of age (1). Summary Topical steroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. Mometasone is FDA-approved for inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses in patients 2 years of age and older. The safety and efficacy of mometasone have not been established in pediatric patients below 2 years of age (1). Mometasone is commercially available in the following dosage forms: topical cream, topical lotion, topical ointment, nasal spray and as powder for inhalation. Mometasone powder may be considered medically necessary in a topical formulation for patients 2 years of age or older for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Mometasone powder may be considered investigational in a topical formulation for patients Mometasone Powder FEP Clinical Rationale MOMETASONE POWDER under the age of 2 years, or in patients without a diagnosis of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]